Skip to main content
. 2023 Apr 26;10:1142429. doi: 10.3389/fcvm.2023.1142429

Table 2.

Selected economic evaluations of catheter ablation for atrial fibrillation.

Study (Year) Patient population Analysis/Methodology Country Intervention vs. Comparator Time Horizon Currency Incremental Cost Effectiveness Ratio Reference
McKenna (2009) Patients with paroxysmal AF refractory to medical therapy CUA/Markov model United Kingdom Catheter ablation vs. AAD Lifetime 2006 GBP £7763–£7910/QALY (34)
Blackhouse (2013) Patients with drug-refractory AF CUA/Markov model United States Catheter ablation vs. amiodarone 5 years 2010 CDN $59,194/QALY (35)
Aronsson (2015) Patients with symptomatic, antiarrhythmic drug naïve AF within the preceding 6 months. CUA/Markov model Sweden Catheter ablation vs. AAD Lifetime 2012 Euros €50,570/QALY (36)
Chew (2022) Patients with paroxysmal or persistent AF aged ≥65 years or <65 years with ≥1 risk factors for stroke CUA/Trial-based United States Catheter ablation vs. medical therapy Lifetime 2018 USD $57,893/QALY
$183,318/LY
(28)
Catheter ablation in Atrial Fibrillation and Heart Failure
Gao (2019) Patients with concomitant symptomatic AF and HF with reduced EF CEA and CUA/ Markov model Australia Catheter ablation vs. medical therapy Lifetime AUD $55,942/QALY
$35,020/LY
(37)
Chew (2020) Patients with concomitant symptomatic AF and HF with reduced EF CUA/Markov model United States Catheter ablation vs. medical therapy Lifetime 2018 USD $38,496/QALY (38)
Lau (2021) Patients with concomitant symptomatic AF and HF with reduced EF CUA/Markov model Canada Catheter ablation vs. medical therapy Lifetime 2018 CDN $35,360/QALY (30)

AAD, antiarrhythmic drug; AF, atrial fibrillation; AUD, Australian Dollar; CDN, Canadian Dollar; CUA, cost utility analysis; GBP, British Pound Sterling; EF, ejection fraction; HF, heart failure; QALY, quality adjusted life years; LY, life years; USD, US Dollar.